# Biopharma Deal
Episod podcast teratas
Dikemas kini:
Top podcast episodes featuring biopharma deal.
Eli Lilly’s Got A Sparkling New AI Biopharma Deal, And European Inflation Fears Are Rising
The US maker of Zepbound just signed a $2.75 billion deal with Hong Kong-based Insilico Medicine for an AI-developed drug – while eurozone consumers and businesses say they expect prices to rise… and that suggests they will.
Today’s stories:
Eli Lilly’s Got A Sparkling New AI Biopharma Deal
Inf ...
July 15, 2022
Biopharma watchers have been speculating for weeks about Merck & Co. buying out fellow cancer drugmaker Seagen. But now, the two companies are reportedly nearing a deal. We'll discuss how it could be the largest biopharma deal since 2020—and what might stand in its way.
But that's not all. Ever ...
As biopharma deals keep pace, M&A volumes languish
Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers.
Hosted on Acast. See acast.com/privacy for more information.
Array Deal Gives Pfizer Deep Cancer Expertise: Fazeli
Sam Fazeli, Director of Research for Bloomberg Intelligence, on Pfizer expanding its cancer platform with the $10.6 billion Array BioPharma deal. Leland Miller, CEO of China Beige Book International, on why Xi Jinping and Trump will want to make a deal at the G20. Matt Maley, Managing Director ...
Biotalk Episode 13 2023 Year-In-Review Report: Global Trends in Biopharma Transactions
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2023 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital m ...
Biotalk Episode 15: 2024 Q1 Report: Global Trends in Biopharma Transactions
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, stra ...
Biotalk Episode 17: Q2 2024 Report: Global Trends in Biopharma Transactions
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our Q2 2024 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, stra ...
Biotalk Episode 9 2023 Q3 Report: Global Trends in Biopharma Transactions
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, delves into our 2023 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, ...
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trade-offs companies face, the litigation risks around mandatory Medicare MFN pricing demon ...
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major biopharma deals, and Israel Ortiz makes the case for preventive maintenance in manufacturing.
ENJIN PENCARIAN PODCAST
Anda boleh menggunakan tapak web kami untuk mencari podcast3,832,333dan episod196,982,668mengikut orang, tempat atau topik.
Pelaburan dalam ilmu memberikan pulangan terbaik, jadi saya mendengar podcast.
‐ Benjamin "Llamacorn" Franklin
SUNTING
Terima kasih kerana membantu memastikan pangkalan data podcast dalam keadaan terkini.
